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Introduction
Obesity-related comorbidities such as hypertension, type II 
diabetes and hypertriglyceridemia are linked to increased risk 
of cognitive decline and dementia (1), but an understanding 
of the combined risk due to multiple risk factors on cognitive 
health is limited. Metabolic syndrome (MetS) is a clinical entity 
associated with underlying insulin resistance with a cluster of 
at least three of five cardiovascular risk factors (central obesity, 
hypertension, hypertriglyceridemia, HDL-cholesterol (HDL-
C) and impaired glucose metabolism) (2). Early identification 
and treatment of individuals with MetS at risk of cognitive 
impairment may be of significant value in reducing the risk of 
metabolic and cognitive decline (1). However, the nature of the 
association between MetS and cognition is unclear (3), whether 
the combined risk of concurrent metabolic disorders in MetS 
has a negative impact on specific cognitive function in older 
persons (4). A French study found that hypertriglyceridemia, 
low HDL-C, and diabetes, but not elevated fasting glucose, 
were associated with a steeper cognitive decline (5), suggestive 
that the clustered cardiovascular risk might have an important 
association with cognitive performance.
Current evidence in studying the relationship between MetS 
and cognition is inconclusive in part due to the use of clinical 
measures for MetS in research that provides no information 
on risk severity (6). The dichotomous classification of the 
presence of the clinical syndrome uses arbitrary cut-offs for the 
components (i.e., the presence or absence of central abdominal 
obesity, hypertriglyceridemia, reduced high-density lipoprotein, 
hypertension and impaired fasting glucose) (2). While the 
dichotomous clinical definition of the presence or absence of 
MetS has limitations, small changes in the component values 
could result in a change in the clinical status of having or not 
having MetS, particularly in individuals having borderline 
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standardized beta=0.26, SE 0.11, p<0.05) and higher Trail Making B scores (adjusted beta=0.23, SE 0.11, 
p<0.05). Higher MetS risk was related to lower cognitive performance. Conclusion: Combined risk due to 
multiple risk factors in MetS was related to lower global cognitive performance and executive function. A higher 
MetS risk burden may point to opportunities for cognitive testing in older adults as individuals may experience 
cognitive changes.
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values and multiple components of the syndrome. One approach 
to addressing the clustering effect of cardiovascular risk factors 
in epidemiological studies is statistical z-score standardization 
to construct a continuous risk estimate (6).
Because of subclinical manifestation of dementia before 
the diagnosis, estimating the risk of MetS in older people at 
risk of cognitive deterioration might provide an opportunity 
for early detection and insight into new avenues for disease-
course modification (1). This study hypothesized that MetS 
risk severity is related to cognitive performance in adults with 
memory complaints. The objective was to identify the cognitive 
patterns in relation to MetS using the clinical criteria, its 
associated risk severity using z-scores and increasing numbers 
of components. 
Materials and Methods
This study analysed the baseline data of the Australian 
Imaging Biomarkers & Lifestyle (AIBL) Active randomized 
controlled trial study participants, who were community-
dwelling older adults aged over 60 years with mild cognitive 
impairment (MCI) or subjective memory complaints and at 
least one cardiovascular risk factor including physical 
inactivity, obesity, hypertension, heart disease, diabetes, 
smoking and dyslipidemia (7). The AIBL Active trial 
investigated whether a 24-month physical activity program can 
delay the progression of white matter changes on neuroimaging 
(8) and the trial participants were recruited from the AIBL 
flagship study, a multidisciplinary prospective study of aging 
previously described (9). Those with a diagnosis of dementia 
based on Mini-Mental State Examination (MMSE) (10), 
depression at baseline and severe visual or hearing impairment 
were not included (7). All participants provided written consent. 
Ethics approval for AIBL Active study analyses was obtained 
from the Melbourne Health Human Research Ethics Committee.
Trained research assistants overseen by neuropsychologists 
administered a battery of neurocognitive tests at baseline 
to assess global cognition, verbal memory and executive 
functioning as per the protocol paper (7). An MMSE (0-30) 
score of less than 24 excluded participants from the study (10). 
Lower MMSE and higher Alzheimer’s disease Assessment 
Scale-Cognitive Section (ADAS-cog, 0-70) (11) scores 
indicate increased severity of global cognitive impairment. The 
Consortium to Establish a Registry for Alzheimer’s Disease 
(CERAD) tool (12) was used for classification of MCI. The 
individual tests of CERAD in verbal fluency and delayed recall 
were used to assess executive function and verbal memory 
respectively. Trail making tests (TMT) A & B are two parts 
of an executive function test that provides information about 
visual scanning, processing speed and mental flexibility. 
Waist circumference was measured three times, according to 
the standardized protocol. Resting seated blood pressure (BP) 
was assessed as the mean of five measurements at two-minute 
intervals using a digital monitor. For cardiovascular health and 
medications, a physician-researcher adjudicated the medical 
records obtained from each participant’s doctor. Blood samples 
for analysis of vascular risk factors were collected at baseline 
and analyzed at a certified laboratory (Melbourne Pathology, 
VIC). The National Cholesterol Education Program Adult’s 
Treatment Panel (NCEP-ATP) III clinical definition of MetS 
was used (2).
All analyses were conducted using Stata (v23.1 Stata Corps). 
Standardized z-scores were constructed with lower scores 
indicating a favorable MetS risk profile. The construct is 
consistent with the research practice according to the American 
Diabetes Association and the European Association for the 
Study of Diabetes (6). The z-score was defined as the sum of 
z-scores of the waist, BP, fasting HDL-C, triglycerides and 
glucose. The HDL-C z-scores were multiplied by -1 for the 
inverse protective relationship with cardiovascular risk (6). The 
resulting z-score combines individual components for a person 
and represents the combined risk burden.
Table 1
Characteristics of participants with and without metabolic 
syndrome
Variables (mean + SD) Metabolic syndrome
Yes (n=31) No (n=77)
mean SD mean SD
Age (years) 73.4 5.0 73.1 6.1
Female, n (%) 13 41.9 44 57.1
Smoking history,n (%) 12 40 28 36.4
Education (years) 13.6 3.2 14.3 3.8
Waist (cm) 100.1 14.1 86.8 11.0
Systolic blood pressure (mmHg) 126.0 15.5 126.7 15.7
Diastolic blood pressure (mmHg) 71.5 7.7 72.6 8.9
Triglyceride (mg/dL) 1.7 0.8 1.1 0.4
HDL-C (mg/dL) † 1.3 0.4 1.6 0.4
LDL-C (mg/dL) ‡ 2.8 1.3 3.2 0.8
Cholesterol (mg/dL) 4.9 1.4 5.3 0.9
Glucose (mg/dL) 5.8 1.2 5.2 1.1
Treatment for
  Hypertension, n (%) 22 71.0 25 32.5
  Diabetes Mellitus, n (%) 6 19.4 3 3.9
  Dyslipidemia, n (%) 21 67.7 27 35.1
Metabolic syndrome (z) 2.2 2.6 -1.0 2.4
Variables are presented as mean and SD unless otherwise stated. †HDL-C: High-density 
lipoprotein – cholesterol; ‡LDL-C: low-density lipoprotein – cholesterol
Cognitive test scores were compared between the two 
groups (with and without MetS) using independent t-tests. The 
associations of each cognitive test and MetS were assessed 
in separate univariate regression models. The analyses were 
repeated using multivariate regression to adjust for age, gender 
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and education. Likelihood ratio (LR) tests compared the models 
of fit to assess the quality of the models using MetS measures 
as continuous (z-score) or discrete (number of components). 
MetS entered the multivariate regression models according 
to the presence or absence of MetS clinical status (model 1), 
continuous MetS z-scores (model 2) and the total number of 
MetS components (model 3). Each cognitive test was fitted 
separately to the models. It was determined that a sample size 
of 108 would provide approximately 80% power to detect a 
two-point difference between groups with a significance level 
0.05 based on SD 3.5 in ADAS-cog  and the national estimates 
of cardiovascular factor clustering (>3) of prevalence about 
30% (13).
Results
MetS was observed in 31 participants (28.7%). The 
characteristics of the participants are shown in Table 1. There 
were no inter-group differences in cognitive performance (p 
>0.05) (not shown). ADAS-cog had a weak positive correlation 
with age (r=0.19, p<0.05), a negative correlation with 
education in years (r=-0.26, p<0.01). It also had a moderate 
positive correlation with MetS (r=0.26, p<0.05)) as well 
as its components of waist circumference (r=0.20, p<0.05) 
and fasting glucose (r=0.28, p<0.05) but had no significant 
correlations with BP, triglycerides and HDL-C (table 2). MetS 
z-scores were significantly associated with gender (M:1.39 v 
F:1.32, p<0.001). 
In the univariate analyses (not shown), MetS z-scores had 
significant associations with poorer global cognition, with 
higher ADAS-cog (beta=0.35, p<0.01) and lower CERAD 
delayed recall (beta=-0.19, p<0.01). In the multivariate analyses 
(table 3), MetS clinical status was not significantly associated 
with performance on cognitive tests. A higher z-score was 
associated with poorer global cognition, with higher ADAS-cog 
(adjusted beta=0.26, p<0.05) and TMT B (adjusted beta=0.23, 
p<0.05) after adjustment for covariates. An increasing number 
of MetS components was significantly associated with higher 
TMT B (adjusted beta=0.20, p<0.05). There was no evidence 
that the association between cognitive measures and MetS 
continuous model (z-scores) was a better fit than the discrete 
model (number of components) (LR tests p<0.05). Omitting 
one outlier in TMT B did not change the significance of the 
associations. Residual analyses for the normality assumptions 
of the regression models were deemed acceptable.
Table 2
Correlation coefficients between global cognition (ADAS-cog) according to metabolic syndrome (MetS) and its component 
factors (z-scores) (n = 108)
                                 Risk factors Metabolic Syndrome Factors
Variables                  MetS (z) Waist (z) BP (z) TAG (z) HDL-C (z) Glucose (z)
Age (years) 0.13 0.05 0.19* 0.07 -0.04 0.04
Education (year) -0.05 -0.06 0.11 -0.03 0.05 -0.14
Global cogntion (ADAS-cog) 0.26* 0.20* 0.07 -0.03 -0.17 0.28*
MetS: metabolic syndrome, TAG: triglycerides, HDL-C: high-density lipoprotein-cholesterol. ADAS-cog: Alzheimer’s Disease Assessment Scale-Cognitive Subscale
Table 3
Standardized estimates of separate multivariate linear regression models showing the relationship between cognitive tests 
(dependent variable) and metabolic syndrome (MetS) (independent variable), adjusted for age, gender and education in years
Cognitive tests§ MMSE ADAS-cog CDR TMT A TMT B Verbal Fluency Delayed recall
MetS † Model n 106 106 106 103 103 106 106
1. Clinical criteria ‡ (y/n) β 0.09 0.06 -0.09 -0.11 0.16 0.02 -0.03
SE 0.10 0.10 0.09 0.10 0.10 0.10 0.10
2. Risk burden (z-score) β -0.07 0.22* 0.06 0.11 0.25* 0.08 -0.20
SE 0.11 0.10 0.10 0.11 0.11 0.11 0.11
3. Number of MetS † factors β 0.13 0.08 -0.08 -0.01 0.21* 0.02 -0.12
SE 0.10 0.10 0.09 0.10 0.10 0.10 0.10
*P<0.05. †MetS: MetS; ‡MetS clinical status according to the National Cholesterol Education Program Adult Treatment Panel (NCEP-ATP) III criteria coded as 0/1 for yes/no; §MMSE: 
Mini-Mental Status Examination, ADAS-cog: Alzheimer’s Disease Assessment Scale-Cognitive Subscale, CDR: Clinical Dementia Rating Scale; TMT: Trail Making Test. 
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Discussion
This research highlighted the relevance of the risk burden 
in MetS and its association with cognitive performance in 
the study participants who were older adults with memory 
complaints or mild cognitive impairment. Abdominal obesity 
and fasting glucose levels were components of MetS and 
had positive correlations with reduced global cognition. The 
relationship between the global cognition and z-scores in our 
participants is consistent with the longitudinal Three-City 
Study (5), in which MetS was associated with a decline in 
global cognition, although this French study has a lower MetS 
prevalence of 15.8% using NCEP-ATP III definition. The 
relationship between TMT B and MetS (z-scores and number of 
components) in our findings is consistent with a Korean study, 
in which significantly lower TMT B scores were observed in 
older participants with MetS (14). TMT is sensitive in detecting 
inefficiencies in psychomotor speed and executive function, 
relating to frontal lobe functions that may reflect the initial 
cognitive changes in the prodromal stage of vascular-related 
pre-dementia. 
Our study sample is representative of the general 
Australian population concerning cardiovascular risk, with a 
similar prevalence of MetS affecting one-third of the general 
population (13). The standardized continuous variable of 
MetS was more sensitive to cognitive associations than the 
presence or absence of MetS variable. A continuous z-score or 
ordered categorical measure would more closely approximate 
individuals’ actual continuum of risk when compared with the 
dichotomous clinical status of the syndrome (6). The adjusted 
unstandardized coefficient for ADAS-cog of 0.35 indicates that 
improving cognitive function and decreasing the ADAS-cog by 
3.5 points would arise from a lower vascular burden of MetS 
z-score by 0.1 units.
Mechanisms underlying cognitive deficits in MetS may 
be beyond atherosclerosis, contributing to microvascular and 
macrovascular disease. Current views suggest that MetS is 
a multiplex risk factor arising from insulin resistance and 
abnormal adipose deposition and is associated with vascular 
endothelial damage and reduces cerebrovascular blood flow 
that may increase the risk of cognitive impairment (15). Insulin 
resistance and hyperinsulinemia decrease glucose use and 
energy metabolism in the cerebral cortex and may contribute 
to amyloid deposits and phosphorylation of tau protein (16). 
Cholesterol is a significant component of cell membranes 
and myelin. Modification of cholesterol distribution in the 
membrane appears to decrease this membrane fluidity in the 
hippocampus, the memory centre affected early in Alzheimer’s 
disease (17).
This study provides comprehensive, objective measures, 
as opposed to a single screening test to indicate cognitive 
function. The result may be applied to community-dwelling 
older adults at high risk of cognitive decline with one or more 
cardiovascular risk factors, but not to people with dementia 
and healthy adults without cognitive complaints, patients with 
depression, severe hearing loss or visual impairment, because 
they were excluded from the study. The cross-sectional study 
design and the possibility of residual confounding limit the 
inference of causality between cognition, protective factors and 
cardio-metabolic risk factors.
Conclusions
MetS risk was associated with poorer global cognitive 
performance and executive function. A higher MetS risk burden 
in patients might prompt clinicians to consider cognitive testing 
as individuals might experience cognitive changes. Further 
prospective studies should explore its predictive value in 
vascular cognitive impairment and determine the mechanisms 
linking them.
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